SHTDF - ChromaDex teams up with Sinopharm for sales of anti-ageing product in China

Life sciences company ChromaDex Corporation (NASDAQ:CDXC) announced an agreement with Sinopharm Xingsha, the health supplement division of Sinopharm Group (OTCPK:SHTDF) (OTCPK:SHTDY) on Friday to speed up sales of its anti-aging compound Tru Niagen in China. Tru Niagen is currently available for sale in the country on several cross-border online and marketplace platforms, mainly through T-mall, and JD. According to the terms of the agreement, ChromaDex’s (CDXC) all existing cross-border operations in this region will be transferred to Sinopharm Xingsha with Sinopharm (OTCPK:SHTDF) investments leveraged to improve consumer awareness of the Tru Niagen brand. “China’s marketplace remains strategically important with more than 260 million people over the age of 60 and it is our intention to become the leading provider of NAD+ boosting supplements in the market.” ChromaDex (CDXC) Chief Executive Rob Fried noted. The deal is in line with ChromaDex’s (CDXC) recently announced China joint venture agreement.

For further details see:

ChromaDex teams up with Sinopharm for sales of anti-ageing product in China